Loading...

Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles

Adel, M ; Sharif University of Technology | 2022

273 Viewed
  1. Type of Document: Article
  2. DOI: 10.1016/j.btre.2022.e00730
  3. Publisher: Elsevier B.V , 2022
  4. Abstract:
  5. This review highlights using nanotechnology in increasing the bioavailability of AP (Apigenin) to enhance its therapeutic efficacy in breast cancer treatment. Breast cancer is one of the most leading causes of cancer death in women both in developed and developing countries. According to several epidemiological and clinical trial studies that indicate progestin-stimulated breast cancer in post-menopausal women; it is necessary to determine compounds to suppress or attenuate the tumor-promoting effects of progestins in breast cells. For this purpose, using the natural anti-progestins, including AP compared with the chemical ones could be significantly effective due to the lack of toxicities and contradiction effects. However, AP is categorized as a Class II drug of Biopharmaceutical Classification System with low solubility in water which limited its therapeutic effects. Therefore, nanotechnology due to the presentation of remarkable properties has overcome this limitation through enhanced the solubility and bioavailability of AP. In this regard, various nanocarriers such as nanocrystals, micelles, liposomes, PLGA, etc., have highlighted the significantly increased bioavailability and therapeutic efficacy of AP. Therefore, we will focus on the anticancer effects of AP in breast cancers, including involved mechanisms, the chemistry of AP and its bioavailability, finally different nanostructure systems to enhance the bioavailability of AP. © 2022
  6. Keywords:
  7. Apigenin ; Bioavailability ; Breast cancer ; Nanostructure systems ; Aromatase inhibitor ; Fatty acid synthase ; Gamma interferon ; Gestagen ; Liposome ; Nanocarrier ; Nanocrystal ; Nanoparticle ; Polyglactin ; Programmed death 1 ligand 1 ; Programmed death 1 receptor ; Protein kinase B ; STAT1 protein ; Transcription factor Yap1 ; Transcriptional coactivator with PDZ binding motif protein ; Angiogenesis ; Apoptosis ; BT-474 cell line ; Cancer cell ; Cancer chemotherapy ; Cancer therapy ; Cardiovascular risk ; Cell cycle arrest ; Clinical trial (topic) ; Conjunctivitis ; Coronavirus disease 2019 ; Female ; HCT 116 cell line ; Human ; Human cell ; Immune response ; MCF-7 cell line ; MDA-MB-231 cell line ; MDA-MB-453 cell line ; MDA-MB-468 cell line ; Metastasis ; Micelle ; Mucosa inflammation ; Nanotechnology ; Non insulin dependent diabetes mellitus ; Pancreas cancer ; Phase 3 clinical trial (topic) ; Phosphorylation ; Postmenopause ; Review ; Phase 2 clinical trial (topic)
  8. Source: Biotechnology Reports ; Volume 34 , 2022 ; 2215017X (ISSN)
  9. URL: https://www.sciencedirect.com/science/article/pii/S2215017X22000297